Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

C4 THERAPEUTICS, INC.

(CCCC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société C4 THERAPEUTICS, INC.
01/21C4 THERAPEUTICS : Financial Statements - Form 8-K/A
PU
01/21C4 THERAPEUTICS, INC. Financial Statements and Exhibits (form 8-K/A)
AQ
01/10C4 THERAPEUTICS : Announces 2022 Key Milestones to Advance Targeted Protein Degradation Po..
PU
01/10C4 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Discl..
AQ
01/10C4 THERAPEUTICS : Corporate Presentation – January 2022
PU
01/10C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P..
GL
01/03C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
GL
2021C4 THERAPEUTICS : CFT7455 ASH Trial-in-Progress Poster Presentation
PU
2021C4 Therapeutics Added to NASDAQ Biotechnology Index
GL
2021C4 THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct F..
AQ
2021C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Res..
PU
2021C4 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
2021C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Res..
GL
2021BRD9 TPD Summit Presentation
PU
2021CFT8919 TPD Summit Presentation
PU
2021C4 THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2021C4 THERAPEUTICS : Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF..
PU
2021C4 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Discl..
AQ
2021C4 THERAPEUTICS : Reports Recent Business Highlights and Second Quarter 2021 Financial Res..
AQ
2021C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of ..
GL
2021C4 THERAPEUTICS : Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the ..
PU
2021C4 THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Regulation FD..
AQ
2021C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underw..
GL
2021C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the..
GL
2021C4 Therapeutics Announces Pricing of Public Offering
GL
2021C4 THERAPEUTICS : Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT..
PU
2021C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021C4 Therapeutics Launches Proposed Public Offering
GL
2021C4 THERAPEUTICS : Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT..
AQ
2021C4 THERAPEUTICS : Pre-clinical Data Support Plans to Advance CFT8919 to Clinical Developme..
PU
2021C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L85..
GL
2021C4 THERAPEUTICS : CFT8919 Pre-Clinical Data
PU
2021C4 THERAPEUTICS : CFT8919 Pre-clinical Data on EGFR L858R-driven NSCLC to be Presented at ..
PU
2021C4 THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
2021C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabli..
GL
2021C4 THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements an..
AQ
2021C4 Therapeutics Appoints Lauren White as Chief Financial Officer
GL
2021C4 THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2021C4 THERAPEUTICS : Reports Recent Business Highlights and First Quarter 2021 Financial Resu..
AQ
2021C4 Therapeutics to Present at Upcoming Investor Conferences
GL
2021C4 THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the ..
GL
2021C4 THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2021C4 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Change in Directors..
AQ
2021C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results
GL
2021C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a M..
GL
2021C4 Therapeutics to Participate in Upcoming March Investor Conferences
GL
2021C4 Therapeutics to Participate in BMO BioPharma Spotlight Series
GL
2021C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT..
GL
2021C4 THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
2021C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
GL
2021C4 THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
2021C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four C..
GL
2020C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
GL
2020C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx
GL
2020C4 THERAPEUTICS : to Present at the Evercore ISI 3rd Annual HealthCONx
AQ
2020C4 THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
2020C4 THERAPEUTICS : to Present at the Jefferies Virtual London Healthcare Conference
AQ
2020C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
GL
2020C4 THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2020C4 THERAPEUTICS : Reports Business Highlights and Third Quarter 2020 Financial Results
AQ
2020C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results
GL
2020C4 THERAPEUTICS : to Present at the 3rd Annual Targeted Protein Degradation Summit
AQ
2020C4 Therapeutics to Present at the 3rd Annual Targeted Protein Degradation Summit
GL
2020C4 THERAPEUTICS, INC. : Change in Directors or Principal Officers, Amendments to Articles ..
AQ
2020C4 THERAPEUTICS : Announces Closing of Initial Public Offering and Full Exercise of the Un..
AQ
2020C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the U..
GL
2020C4 THER : Therapeutics Announces Pricing of an Upsized Initial Public Offering
AQ
2020C4 Therapeutics Announces Pricing of an Upsized Initial Public Offering
GL
Upcoming event on C4 THERAPEUTICS, INC.